Human Growth Hormone Market Size Worth $15.66 Billion By 2032 | CAGR: 11.4%

The global human growth hormone market size is expected to reach USD 15.66 billion by 2032, according to a new study by Polaris Market Research. The report “Human Growth Hormone Market Share, Size, Trends, Industry Analysis Report, By Type (Long-acting, Short-acting & Intermediate-acting); By Route of Administration; By Age; By Indication; By Distribution Channel; By Region; Segment Forecast, 2023- 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The scope of the Human Growth Hormone (HGH) market encompasses various dimensions that define its reach, applications, and influencing factors. The market caters to therapeutic applications of HGH, addressing medical conditions such as growth hormone deficiencies in children and adults. HGH is used to stimulate growth and development in individuals with insufficient endogenous growth hormone production.

A significant portion of the market focuses on addressing pediatric growth disorders, including conditions like short stature due to growth hormone deficiencies. HGH therapy is a common intervention to promote linear growth in children. The market extends its scope to adults with growth hormone deficiencies, where HGH is used to address conditions such as AGHD. This involves addressing health issues associated with insufficient growth hormone production in adulthood. There is a growing segment within the market that caters to anti-aging and wellness applications. HGH is sometimes used for its perceived anti-aging effects, including improvements in skin health, energy levels, and overall well-being.

Furthermore, HGH is employed in the treatment of muscle-wasting conditions and metabolic disorders. The market addresses the therapeutic use of HGH to mitigate the effects of muscle loss and improve metabolic functions in certain patient populations.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/human-growth-hormone-market/request-for-sample

The high prevalence of growth hormone deficiency (GHD), the increasing need for treatment owing to serious risks associated with GHD, and the rising demand for medications that reduce the frequency of injections are the major factors contributing to the growth of the human growth hormone market.

Factors such as increasing cases of pituitary dysfunction and the development of more advanced technologies to enhance patient adherence to the treatment contribute to the market growth. The rising emphasis of industry players on research & development activities coupled with the strong pipeline of somatropin is expected to drive the market growth during the forecast period.

Increasing awareness related to appropriate treatment coupled with the growing initiatives by public and private organizations related to the treatment of human growth deficiency are expected to prove beneficial for the expansion of the human growth hormone market. Moreover, the increasing number of patients suffering from rare diseases across developing countries will also contribute to the market growth.  

Human Growth Hormone Market Report Highlights

• The long-acting segment is projected to expand at the highest CAGR during the forecast period, owing to the safety profile & effectiveness of long-acting human growth hormones. 
• In 2023, the growth hormone deficiency segment accounted for the largest market share, owing to the high prevalence of the disease and the rising number of new products for its treatment.
• In 2023, the hospital pharmacies segment accounted for the largest market share, owing to the increasing number of patient visits to hospitals.
• North America accounted for the largest revenue share in the human growth hormone market in 2023, owing to the rising cases of Turner syndrome and growth hormone deficiencies. 
• The market players include AnkeBio Co., Ltd, Ascendis Pharma, Novo Nordisk, Pfizer, Eli Lilly, Sandoz International, Merck, Genentech, and more.

Polaris Market Research has segmented the human growth hormone market report based on type, route of administration, age, indication, distribution channel, and region:

Human Growth Hormone, Type Outlook (Revenue - USD Billion, 2019 - 2032)

• Long-acting
• Short-acting & Intermediate-acting

Human Growth Hormone, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

• Oral
• Parenteral
  • Intravenous
  • Subcutaneous
  • Intramuscular

Human Growth Hormone, Age Outlook (Revenue - USD Billion, 2019 - 2032)

• Pediatric
• Adult

Human Growth Hormone, Indication Outlook (Revenue - USD Billion, 2019 - 2032)

• Growth Hormone Deficiency
• Turner Syndrome
• Idiopathic Short Stature
• Prader-Willi Syndrome
• Others

Human Growth Hormone, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

• Hospital Pharmacies
• Retail Pharmacies & Drug Stores
• Online Pharmacies

Human Growth Hormone, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of APAC
• Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of LA
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of MEA

Human Growth Hormone Market Report Scope